Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: A case series

Endocrine Practice

Volumn 18, Issue 3, 2012, Pages 351-355

  Min, Le ^a   Vaidya, Anand ^a   Becker, Carolyn ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; IPILIMUMAB; LUTEINIZING HORMONE; SOMATOMEDIN C; TESTOSTERONE; THYROTROPIN; THYROXINE;

ADRENAL INSUFFICIENCY; ADULT; ADVANCED CANCER; ADVANCED MELANOMA; AGED; CANCER DIAGNOSIS; CAUSE OF DEATH; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DIZZINESS; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ENLARGED PITUITARY; FATIGUE; FEMALE; FREE THYROXINE INDEX; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; HYPOPHYSIS; HYPOPHYSIS DISEASE; HYPOPHYSIS FUNCTION; HYPOPHYSITIS; HYPOPITUITARISM; MALE; MELANOMA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN SIZE; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ADRENAL INSUFFICIENCY; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; DRUG MONITORING; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 84861078121     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP11273.OR     Document Type: Review

References (12)

1. Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P. Ipilimumab. Nat Rev Drug Discov. 2011; 10:411-412.
2. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol. 2001;19:565-594.
3. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic mela-noma (Erratum in: N Engl J Med. 2010;363:1290). N Engl J Med. 2010;363:711-723.
4. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic mela-noma. N Engl J Med. 2011;364:2517-2526.
5. Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol. 2011;164:303-307.
6. Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypoph-ysitis: Serious immune related adverse events across a spec-trum of cancer subtypes. Pituitary. 2010;13:29-38.
7. Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic mela-noma and renal cancer. J Immunother. 2005;28:593-598.
8. Downey SG, Klapper JA, Smith FO, et al. Prognostic fac-tors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13:6681-6688.
9. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15:5591-5598.
10. Ueda H, Howson JM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to auto-immune disease. Nature. 2003;423:506-511.
11. Chistiakov DA, Turakulov RI. CTLA-4 and its role in autoimmune thyroid disease. J Mol Endocrinol. 2003;31: 21-36.
12. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol. 2005;23:741-750.